Ifn-β1B Treatment of Relapsingmultiple Sclerosis Has no Effect on Cd3-Induced Inflammatory or Counterregulatory Anti-Inflammatory Cytokine Secretion Ex Vivo After Nine Months

International Journal of Neuroscience

Volumn 90, Issue 42006, 1997, Pages 135-144

  Brod, Staley A ^a   Nelson, Laura D ^a   Khan, M ^a   Wolinsky, J S ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

IFN 1b; IFN ; IL 10; IL 2; IL 4; IL 6; Multiple sclerosis; TNF

Indexed keywords

BETA INTERFERON; CD3 ANTIGEN; CONCANAVALIN A; CYTOKINE; DIAGNOSTIC AGENT; GAMMA INTERFERON; INTERLEUKIN DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOLOGY; MALE; METABOLISM; MULTIPLE SCLEROSIS; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; ANTIGENS, CD3; CONCANAVALIN A; CYTOKINES; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON TYPE II; INTERFERON-BETA; INTERLEUKINS; MALE; MULTIPLE SCLEROSIS; RECURRENCE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0030829048     PISSN: 00207454     EISSN: 15635279     Source Type: Journal    
DOI: 10.3109/00207459709000633     Document Type: Article

References (32)

1. Arnason B., Jensen M., Lledo A., Dayal A. Interferon γ (IFN-γ)-secreting cells in multiple sclerosis (MS) treated with interferon β1b. Neurology 1995; 45: 2173 – 2177
2. Antel J. P., Freedman M. S., Brodsovsky S., Francis G. S., Duquette P. Activated suppressor cell function in severely disabled patients with multiple sclerosis. Annals of Neurology 1989; 25: 204 – 207
3. Balkwill F. R. The regulatory role of interferons in the human immune response. Interferons: Their impact in biology of medicine, J. Taylor-Papadimitriou. Oxford Medical Publications, Oxford UK 1985; 61 – 80
4. Baxevanis C. N., Reclos G. J., Ansenis P., Anastasopoulaos E., Katsiyiannis A., Lymberi P., Mitikas N., Papamichail M. Decreased expression of HLA-Dr antigens on monocytes in patients with MS. Journal of Neuroimmunology 1989; 22: 177 – 183
5. Baxevanis C. N., Reclos G. J., Papamichail M. Decreased HLA-Dr antigen expression in monocytes causes impaired suppressor cell activity in multiple sclerosis. Journal of Neuroimmunology 1990; 27: 4166 – 4171
6. Bettens S., Walker C., Gauchat J.-F., Gauchat D., Wyss T., Pichler W. J. Lymphokine gene expression related to CD4 T cell subset CD45R/CDw29) phenotype conversion. European Journal of Immunology 1987; 19: 1569 – 1574
7. Bottomly K., Luqman M., Greenbaum L., Carding S., West J., Pasqualini H., Murphy D. B. A monoclonal antibody to murine CD45R distinguishes CD4 T cell populations that produce different cytokines. European Journal of Immunology 1989; 19: 617 – 623
8. Brod S. A., Khan M., Marshall G. D., Henninger E. M., Wolinsky J. S. IFN-β-1b [Betaseron] treatment of relapsing-remitting multiple sclerosis decreases CD3-mediated TNF-α and increases CD3-mediated IL-6 production in vitro. Neurology 1996; 46: 1633 – 1638
9. Budd R. C., Cerottinini J. C., MacDonald H. R. Selectively increased production of IFN-γ by subsets of Lyt-2+ and L3T4+ T cells identified by expression of Pgp-1. Journal of Immunology 1987; 138: 3583 – 3586
10. Byrne J. A., Butler J. L., Cooper M. D. Differential activation requirements for virgin and memory T cells. Journal of Immunology 1988; 141: 3249 – 3257
11. Durelli L., Bongioanni M. R., Cavallo R., Ferraro B., Ferri R., Ferrio M. F., Bradac G. B., Riva A. Chronic systemic high-dose recombinant interferon alpha-2a reduces exacerbation rate. MRI signs of activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis. Neurology 1994; 44: 406 – 413
12. Gauldie J., Richards C., Harnish D., Lansdorp P., Baumann H. Interferon-β/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proceedings of the National Academy of Sciences (USA) 1987; 84: 7251 – 7255
13. IFNB MS Study Group. Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 662 – 667
14. IFNB MS Study Group. Interferon-beta lb is effective in relapsing-remitting multiple sclerosis, I. Clinical results of a multicenter, randomized, double blind, placebo-controlled trial. Neurology 1993; 43: 655 – 661
15. IFNB MS Study Group. Interferon beta-lb in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial. Neurology 1995; 45: 1277 – 1285
16. Horgan K. J., Seventer G. A. V., Shimizu Y., Shaw S. Hyporesonsiveness of “naive” (CD45RA+) human T cells to multiple receptor mediated stimuli but augmentation of responses by co-stimuli. European Journal of Immunology 1990; 20: 1111 – 1120
17. Jacobs L., Cookfair D., Rudick R., Herndon R., Richert J., Salazar A., Fischer J., Granger C. Results of a phase III trial of intramuscular recombinant beta interferon as treatment for multiple sclerosis. Annals of Neurology 1994; 36 (2) 259
18. Koulova L., Yang S. Y., Dupont B. Identification of the anti-CD3-unresponsive sub-population of CD4+CD45RA+ peripheral T lymphocytes. Journal of Immunology 1990; 145: 2035 – 2043
19. Morimoto C., Letvin N. L., Diastaso J. A., Aldrich W. R., Sclossman S. F. The isolation and characterization of the human suppressor inducer T cell subset. Journal of Immunology 1985; 134: 1508 – 1512
20. Morimoto C., Letvin N. L., Rudd C. E., Hagan M., Takeuchi T., Sciossman S. F. The role of the 2H4 molecule in the generation of suppressor function in Con A-activated T cells. Journal of Immunology 1986; 137: 3247 – 3253
21. Noronha A., Toscas A., Jensen M. A. IFN-β decreases T cell activation and IFN-γ production in multiple sclerosis. Journal of Neuroimmunology 1993; 46: 145 – 154
22. Porrini A., Gambi D., Reder A. Interferon effects on IL-10 secretion—mononuclear cell response to IL-10 is normal in multiple sclerosis patients. Journal of Neuroimmunology 1995; 61: 27 – 34
23. Poser C. M., Paty D. W., Scheinberg L., MaDonald W., Davis F., Ebers G., Johnson K., Sibley W. New diagnostic criteria for multiple sclerosis. Annals of Neurology 1983; 13: 227 – 231
24. Powrie F., Correa-Olivirera R., Mauze S., Coffman R. Regulatory interactions between CD45R Bhigh and CD45R Bfow CD4+ T cells are important for a balance between protective and pathogenic cell-mediated immunity. Journal of Experimental Medicine 1994; 179: 589 – 600
25. Quality Standards Committee. A. Practice advisory on selection of patients with multiple sclerosis for treatment with Betaseron. Neurology 1994; 44: 1537 – 1539
26. Robinson A. T., Miller N., Alexander D. R. CD3 antigen-mediated calcium signals and protein kinase C activation are higher in CD45RO+ than in CD45RA+ human T lymphocyte subsets. European Journal of Immunology 1993; 23: 61 – 68
27. Rudick R. A., Carpenter C. S., Cookfair D. L., Tuohy V. K., Ransahoff R. M. In vitro and in vivo inhibition of mitogen-driven T-cell activation by recombinant interferon-beta. Neurology 1993; 43: 2080 – 2087
28. Salmon M., Kitas G. D., Bacon P. A. Production of lymphokine mRNA by CD45R+ and CD45R- helper T cells from human peripheral blood and by human CD4+ T cell clones. Journal of Immunology 1989; 143: 907 – 912
29. Sanders M. E., Makgoba M. W., June C. H., Young H. A., Shaw S. Enhanced responsiveness of human memory T cells to CD2 and CD3 receptor mediated activation. European Journal of Immunology 1989; 19: 803 – 808
30. Spear G. T., Paulnock D. M, Jordan R. L. Enhancement of monocyte class I and II histocompatibility antigen expression in man by in vivo b interferon. Clinical and Experimental Immunology 1987; 69: 107 – 115
31. Weinstock-Guttmann B., Ransahoff R. M., Kinkel R. P., Rudick R. A. The Interferons: biological effects, mechanism of action and use in multiple sclerosis. Annals of Neurology 1995; 37: 7 – 15
32. Wolinsky J. Multiple Sclerosis. Current Neurology, S. A. Appel, 1993; vol. 13: 167 – 207